Sanofi Rolling (With) DICE in the Bay Area

Home/Financial/Sanofi Rolling (With) DICE in the Bay Area

Sanofi Rolling (With) DICE in the Bay Area

Intro from John Carroll of FierceBiotech reporting on Sanofi’s big collaboration deal with DICE Molecules:

“The last time I crossed paths with Kevin Judice, he was helping Jeff Stein launch San Diego-based Cidara Therapeutics, an antibiotics developer that lay well outside the perimeters of Judice’s home base in the Bay Area. Now Judice, a Genentech veteran and longtime biotech entrepreneur on the West Coast, is gearing up DiCE Molecules, a spinout from a much closer campus at Stanford that’s jumping into the spotlight today with the help of a collaboration with Sanofi’s ($SNY) Sunrise team that starts with $50 million in early-stage cash and support, with the potential to add billions more for a successful lineup of programs.

DiCE is the brainchild of Pehr Harbury, a Stanford professor and biochemist–and MacArthur “genius” award winner–who’s been constructing the building blocks of a platform technology, which is exactly Sanofi’s sweet spot for cutting-edge deals.” Full article

More coverage:

  • Bay Area Startup DiCE Molecules Inks Small Molecule Deal Worth Up to $2.3 Billion with Sanofi (BioSpace)
  • Sanofi Strikes $2.3 Billion Deal With DiCE Molecules (Fortune/Reuters)
  • Sanofi and DiCE Molecules Announce Research Collaboration to Discover Potential Therapeutics Based on Unique Small Molecule Discovery Platform (press release)
March 16th, 2016|